Vivani Medical VANI Biopharm Division — Net Income Loss
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vivani Medical in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vivani Medical's biopharm division — net income loss.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vivani Medical's biopharm division — net income loss?
- Vivani Medical (VANI) reported biopharm division — net income loss of -$6.01M in Q1 2026.
- How has Vivani Medical's biopharm division — net income loss changed year-over-year?
- Vivani Medical's biopharm division — net income loss decreased by 6.5% year-over-year, from -$5.65M to -$6.01M.
- What is the long-term trend for Vivani Medical's biopharm division — net income loss?
- Over 2 years (2023 to 2025), Vivani Medical's biopharm division — net income loss has grown at a 9.2% compound annual growth rate (CAGR), from -$20.26M to -$24.15M.
- What does biopharm division — net income loss mean?
- Measures the profitability of the biopharmaceutical segment by subtracting all segment-specific operating and non-operating expenses from its revenues. As a preclinical-stage entity, this figure typically reflects the net cash outflow required to sustain innovation and technology development. It serves as a primary indicator of the segment's financial sustainability and the scale of investment needed to reach commercialization.